Global Head of Development, Rare Diseases at Sanofi
Appears in 1 story
Leading rilzabrutinib development program
For 50,000 Americans living with warm autoimmune hemolytic anemia, there has never been a treatment specifically designed for their disease. On February 9, 2026, the Food and Drug Administration (FDA) granted breakthrough therapy designation to rilzabrutinib—marking the first time a Bruton's tyrosine kinase (BTK) inhibitor has reached this milestone for the condition. The designation signals the FDA's recognition that this drug may offer substantial improvement over existing therapies.
Updated Feb 9
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
